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published utility values exist. METHODS: Consecutive outpa-
tients with non-small cell lung cancer (NSCLC) attending a major
Canadian cancer centre completed the EORTC QLQ-C30 and
EQ5D on a single visit. Different patient disease states included:
1) relapse-free post-resection, including on preventive chemo-
therapy; 2) in relapse, including on palliative chemotherapy or
targeted therapy (erlotinib); and 3) on chemoradiation for locally
advanced NSCLC. Exploratory correlation of EORTC QLQ-C30
and EQ-5D scores is ongoing. RESULTS: A total of 172 patients
participated. The median age of the sample was 65, (range 32–85
years); 47% were male. Half had advanced NSCLC (51%), 41%
were relapse-free post-resection, and 8% had locally advanced
NSCLC. Nearly half of relapse-free patients received preventive
chemotherapy. Twenty-seven percent of advanced NSCLC
patients were receiving palliative chemotherapy, 35% targeted
therapy with erlotinib, and the rest were not on active treatment.
Utility values (based on the EQ5D) were not signiﬁcantly different
among groups, including by disease status (relapse-free versus
in relapse), and current treatment (chemotherapy, erlotinib or
observation). Mean utilities were similar for relapse-free patients
despite treatment, 0.76, and minor differences were seen among
those in relapse, (on chemotherapy, mean utility 0.69; on erlotinib
0.77, on supportive care, 0.75). Exploratory correlation of
EORTC QLQ-C30 and EQ5D values will be presented. CON-
CLUSIONS: QL values in the derivation of patient utility for
different health states in clinical trials may further the ability to
estimate cost utility of novel therapies in cancer clinical trials.
PCN79
METHODS FOR ASSESSING QUALITY OF LIFE IN CANCER
PATIENTS EXPERIENCING COMPLICATIONS:
OSTEONECROSIS OFTHE JAW PILOT STUDY
Miksad R1,Woo SB2, Dodson T3,Treister NS2, Maytal G3,August M3,
Akinyemi O3, Bihrle MM4, Swan JS3
1Beth Israel Deaconess Medical Center / Institute for Technology
Assessment / Harvard University, Boston, MA, USA, 2Brigham and
Women’s Hospital/ Harvard University, Boston, MA, USA,
3Massachusetts General Hospital/ Harvard University, Boston, MA,
USA, 4Massachusetts General Hospital/ Beth Israel Deaconess
Medical Center/ Harvard University, Boston, MA, USA
OBJECTIVES: Intravenous bisphosphonate use in cancer
patients is associated with exposed and necrotic jaw bone, called
Osteonecrosis of the Jaw (ONJ). The overall aim of this pilot
study was to develop a survey that captured the oral health-
speciﬁc and the global health related quality of life (HRQoL)
impact of ONJ, to test the feasibility of survey instruments and to
assess subject distress. METHODS: A 30 minute phone survey
was created with multi-disciplinary collaboration. Four stan-
dardized ONJ health states were developed and subjects’ prefer-
ences (utility) for each state were obtained using the Visual
Analogue Scale (VAS), the EQ5D and time-tradeoff (TTO) ques-
tions. A Visual Basic Interface was constructed to guide the
interviewer through TTO questions designed for the survey. The
subject’s life before and after ONJ was evaluated with the Oral
Health Impact Proﬁle (OHIP). Emotional discomfort during and
after survey was evaluated on a ﬁve point Likert scale. Subjects
were randomly identiﬁed from a cohort of 80 cancer patients
with ONJ. RESULTS: The pilot study included ﬁve patients
(response rate = 100%). Utility decreased with increasing ONJ
stage for all HRQoL instruments: 0.76, 0.97, 0.86 (Cancer and
No ONJ), 0.72, 0.88, 0.83 (Cancer and Stage 1 ONJ), 0.43,
0.52, 0.63 (Cancer and Stage 2 ONJ) and 0.34, 0.39, 0.56
(Cancer and Stage 3 ONJ) for VAS, EQ5D and TTO respectively.
With a baseline mean of 1.6, the OHIP score increased to 7.2
after ONJ (0–28 scale). Two subjects ranked 2 (“a little”) for the
level of emotional discomfort during the survey, but none were
upset afterwards. CONCLUSIONS: Based on preliminary
results, the study design was feasible and both oral health-speciﬁc
and global HRQoL instruments were sensitive to QoL changes
associated with ONJ. All HRQoL instrument performance
showed appropriate rank ordering and consistent relationship by
ONJ stage. There was minimal subject distress.
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OBJECTIVE: To compare the valuation of ovarian cancer health
states as assessed by the visual analog scale (VAS) and the stan-
dard gamble (SG). METHODS: Ovarian cancer patients and
oncologists were enrolled in this study. Participants were asked to
score six hypothetical treatment scenarios using the VAS and SG.
Values were compared using the intraclass correlation coefﬁcient
(ICC) and t-test. RESULTS: Fifty-one patients and 34 oncologists
were enrolled to this study. Participants were asked to rank order
health states in a one-time interview using the VAS, followed by
assessment of the health states, in random order, using the SG.
This resulted in 244 and 199 SG-VAS data pairs for analysis from
patients and oncologists, respectively. The ICC among patients
was 0.003 (95% CI: -0.122 to 0.129; F-test, p = 0.479). A
signiﬁcant difference was observed between VAS and SG scores
for patients receiving chemotherapy (mean difference, -0.114,
p < 0.0001), but not for patients under surveillance (mean dif-
ference 0.06, p = 0.13). The SG produced higher valuation than
the VAS among patients receiving chemotherapy, but the VAS
produced higher values than the SG among patients under sur-
veillance. For oncologists, the ICC was 0.323 (95% CI: 0.192 to
0.442; F test p < 0.0001), with the SG 0.09 higher than VAS
values (p < 0.0001). Each patient group valued the health states
in the mean range of 0.46–0.61 on the VAS; however, SG utilities
ranged from 0.53–0.61 for patients receiving chemotherapy and
from 0.30–0.37 for patients under surveillance. The range of
mean values by oncologists was 0.27–0.66 and 0.30–0.70 for the
VAS and SG, respectively. CONCLUSION: There appear to be
different utility values obtained using the SG and VAS among
patients undergoing treatment, patients under surveillance, and
oncologists. This comparison suggests the importance of consid-
ering differences between these groups and method used when
conducting utility valuation research in ovarian cancer.
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OBJECTIVE: Patients with breast and colorectal cancer can use
oral and injectable chemotherapy treatments. The objective of
this study is to assess the satisfaction in patients using capecit-
abine (oral chemotherapy) in comparison with their previous
experiences with injectable chemotherapies. Also, we aimed to
compare the preference of patients on this oral drug to the
injectable chemotherapy treatments. METHODS: Quantitative
study performed with 150 oncology patients with breast and
colorectal cancer (from all Brazilian regions) who use capecitab-
ine as a treatment. A structured questionnaire with 10 answers
assessing six attributes was used. RESULTS: The average age of
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